News - Eisai

Filter

Current filters:

Eisai

Popular Filters

1 to 25 of 116 results

Eisai’s breast cancer drug Halaven receives MAA in Europe

Eisai’s breast cancer drug Halaven receives MAA in Europe

03-07-2014

The European Commission has issued Marketing Authorization Approval (MAA) for Halaven (eribulin) from…

EisaiEuropeHalavenOncologyPharmaceuticalRegulation

Boston Strategics in-licenses Eisai’s cancer candidate E6201

01-07-2014

US clinical-stage drug R&D company Boston Strategics Corp has entered into an exclusive licensing and…

Boston Strategics CorpE6201EisaiLicensingOncologyPharmaceutical

Eisai’s Zebinix shown to be effective and well-tolerated

Eisai’s Zebinix shown to be effective and well-tolerated

30-06-2014

Once-daily Zebinix (eslicarbazepine acetate) from Japanese drug major Eisai is effective, retained and…

EisaiEuropeNeurologicalPharmaceuticalResearchZebinix

Eisai files first marketing application for lenvatinib in Japan

Eisai files first marketing application for lenvatinib in Japan

26-06-2014

Japanese pharma major Eisai said today that it has submitted its first marketing authorization application…

EisaiJapanlenvatinibOncologyPharmaceuticalRegulation

Eisai’s Fycompa launches in Russia

Eisai’s Fycompa launches in Russia

09-06-2014

Japanese pharma major Eisai has announced that its epilepsy drug Fycompa (perampanel) has launched in…

EisaiEpilepsyFycompaNeurologicalPharmaceuticalRussia

ASCO 2014 kicks off with news on lenvatinib, Cyramza, olaparib and Recentin

ASCO 2014 kicks off with news on lenvatinib, Cyramza, olaparib and Recentin

01-06-2014

The 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) began on Friday in Chicago,…

AstraZenecaBiotechnologyCyramzaEisaiEli LillylenvatinibolaparibOncologyRecentinResearch

US FDA approves Eisai’s Aloxi for children and extends exclusivity

US FDA approves Eisai’s Aloxi for children and extends exclusivity

29-05-2014

Japanese drug major Eisai announced today that the antiemetic agent Aloxi (palonosetron HCI) has been…

AloxiAntiemeticsEisaiHealth Medical PharmaJapanMedicineOncologyPharmaceuticalRegulationUnited StatesUSAVomiting

Eisai's R&D unit Kan Research Institute starts full-scale operation at new facility

27-05-2014

Japanese drug major Eisai Co says that its R&D subsidiary KAN Research Institute held a dedication ceremony…

BiotechnologyEisaiImmunologicalsJapanKan Research InstituteNeurologicalOncologyResearch

Eisai’s Fycompa debuts in France following reimbursement agreement

21-05-2014

Japanese pharma company Eisai has launched its Fycompa (perampanel), the first in an entirely new class…

EisaiFranceFycompaMarkets & MarketingNeurologicalPharmaceuticalPricing

Eisai expands deal with Biogen; re-files Fycompa with G-BA; news on Zebinix

Eisai expands deal with Biogen; re-files Fycompa with G-BA; news on Zebinix

12-05-2014

Japanese drug major Eisai has exercised its option to jointly develop and commercialize its clinical…

Biogen IdecEisaiFycompaGermanyItalyLicensingNeurologicalPharmaceuticalPricingRegulationZebinix

Eisai to further increase its Belviq sales force by 50%

Eisai to further increase its Belviq sales force by 50%

09-05-2014

USA-based Arena Pharmaceuticals says its marketing partner, Japan’s Eisai, plans to add more than 200…

Arena PharmaceuticalsBelviqEisaiManagementMetabolicsPharmaceuticalUSA

Otsuka acquires certain Dacogen and E7727 rights from Eisai

01-04-2014

Otsuka Pharmaceutical has reached an agreement with the US subsidiary of fellow Japanese drugmaker Eisai…

DacogenE7727EisaiLicensingOncologyOtsukaPharmaceutical

Japan’s Eisai joins forces with UK researchers on tropical disease research

Japan’s Eisai joins forces with UK researchers on tropical disease research

20-03-2014

Japanese drug major Eisai has entered a collaboration with the UK’s Liverpool School of Tropical Medicine…

EisaiPharmaceuticalResearchTropical diseases

Global epilepsy market to reach $4.5 billion by 2019

Global epilepsy market to reach $4.5 billion by 2019

13-03-2014

The epilepsy therapeutics market value in the eight major countries - the USA, Canada, France, Germany,…

EisaiFycompaGlaxoSmithKlineGlobalMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpat

Eisai and Biogen Idec collaborate on Alzheimer’s disease treatments

Eisai and Biogen Idec collaborate on Alzheimer’s disease treatments

05-03-2014

US biotech firm Biogen Idec and Japanese drugmaker Eisai have entered into a collaboration to develop…

BAN2401BIIB037Biogen IdecBiotechnologyE2609EisaiLicensingNeurologicalResearch

Eisai’s lenvatinib meets primary endpoint in Ph III thyroid cancer study

Eisai’s lenvatinib meets primary endpoint in Ph III thyroid cancer study

03-02-2014

Japanese drug major Eisai says that the Phase III SELECT trial (Study 303) of lenvatinib, an investigational…

EisailenvatinibOncologyPharmaceuticalResearch

Eisai’s amatuximab gains orphan status in EU for malignant mesothelioma

Eisai’s amatuximab gains orphan status in EU for malignant mesothelioma

22-01-2014

The investigational monoclonal antibody amatuximab (development code: MORAb-009), has today been granted…

amatuximabEisaiEuropePharmaceuticalRare diseasesRegulation

Ranbaxy cleared to market branded generic of Aricept in Canada

Ranbaxy cleared to market branded generic of Aricept in Canada

08-01-2014

The Canadian subsidiary of Ranbaxy Laboratories has received approval to manufacture and market RAN-Donepezil…

AriceptCanadaDaiichi SankyoEisaiGenericsNeurologicalNorth AmericaRAN-DonepezilRanbaxy LaboratoriesRegulation

Eisai’s epilepsy drug Fycompa to launch in USA

Eisai’s epilepsy drug Fycompa to launch in USA

02-01-2014

The US subsidiary of Japanese pharma major Eisai’s that its epilepsy drug Fycompa (perampanel) will…

EisaiFycompaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalUSA

UK Dementia Consortium to bridge the gap between academia and pharma

UK Dementia Consortium to bridge the gap between academia and pharma

11-12-2013

The UK has today announced a new £3 million ($4.9 million) Dementia Consortium bringing together research…

EisaiEli LillyNeurologicalPharmaceuticalPoliticsResearchUK

1 to 25 of 116 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top